Evidence map›Paper›PMID 22894572›Full record

ArticleThe New England journal of medicine2012

Quality-of-life effects of prostate-specific antigen screening.

Eveline A M Heijnsdijk, Elisabeth M Wever, Anssi Auvinen, Jonas Hugosson, Stefano Ciatto, Vera Nelen, Maciej Kwiatkowski, Arnauld Villers, Alvaro Páez, Sue M Moss and 12 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The New England journal of medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
198citing papers in PubMed, 10 pooled it
39.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

198 citing papers in PubMed, 10 syntheses or guidelines pooled it, 421 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Systematic Review of Cost-Effectiveness Models in Prostate Cancer: Exploring New Developments in Testing and Diagnosis.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2022
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Screening for prostate cancer.The Cochrane database of systematic reviews · 2013
    Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

138 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 12 institutions in 9 countries.

Eveline A M HeijnsdijkDepartment of Public Health, Erasmus Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. e.heijnsdijk@erasmusmc.nl
Elisabeth M Wever
Anssi Auvinen
Jonas Hugosson
Stefano Ciatto
Vera Nelen
Maciej Kwiatkowski
Arnauld Villers
Alvaro Páez
Sue M Moss
Marco Zappa
Teuvo L J Tammela
Tuukka Mäkinen
Sigrid Carlsson
Ida J Korfage
Marie-Louise Essink-Bot
Suzie J Otto
Gerrit Draisma
Chris H Bangma
Monique J Roobol
Fritz H Schröder
Harry J de Koning
Erasmus MC · NLMemorial Sloan Kettering Cancer Center · USCentre Hospitalier Universitaire de Lille · FRCentre International de Recherche sur le Cancer · FRErasmus University Rotterdam · NLHospital Universitario de Fuenlabrada · ESKantonsspital Aarau · CHProvincial Institute for Hygiene · BEQueen Mary University of London · GBSahlgrenska University Hospital · SESeinäjoki University of Applied Sciences · FITampere University Hospital · FI

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundAfter 11 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) reported a 29% reduction in prostate-cancer mortality among men who underwent screening for prostate-specific antigen (PSA) levels. However, the extent to which harms to quality of life resulting from overdiagnosis and treatment counterbalance this benefit is uncertain.

methodsOn the basis of ERSPC follow-up data, we used Microsimulation Screening Analysis (MISCAN) to predict the number of prostate cancers, treatments, deaths, and quality-adjusted life-years (QALYs) gained after the introduction of PSA screening. Various screening strategies, efficacies, and quality-of-life assumptions were modeled.

resultsPer 1000 men of all ages who were followed for their entire life span, we predicted that annual screening of men between the ages of 55 and 69 years would result in nine fewer deaths from prostate cancer (28% reduction), 14 fewer men receiving palliative therapy (35% reduction), and a total of 73 life-years gained (average, 8.4 years per prostate-cancer death avoided). The number of QALYs that were gained was 56 (range, -21 to 97), a reduction of 23% from unadjusted life-years gained. To prevent one prostate-cancer death, 98 men would need to be screened and 5 cancers would need to be detected. Screening of all men between the ages of 55 and 74 would result in more life-years gained (82) but the same number of QALYs (56).

conclusionsThe benefit of PSA screening was diminished by loss of QALYs owing to postdiagnosis long-term effects. Longer follow-up data from both the ERSPC and quality-of-life analyses are essential before universal recommendations regarding screening can be made. (Funded by the Netherlands Organization for Health Research and Development and others.).

Indexed as

Early Detection of CancerQuality-Adjusted Life YearsQuality of LifeAgedDiagnostic ErrorsEuropeFollow-Up StudiesHumansMaleMass ScreeningMiddle AgedProstate-Specific AntigenProstatic NeoplasmsRandomized Controlled Trials as TopicProstate-Specific Antigen

Identifiers

PMID22894572
PMCPMC4982868
OpenAlexW2116556918

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.